An Updated Analysis Evaluating Skeletal Related Events (sres) in CTRIAL-IE 13-21: Phase II Trial of Radium-223 (R223) in Combination with Enzalutamide (ENZA) for Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc).
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要